All terms
Coverage with Evidence Development
Medicare paradigm conditioning coverage on participation in approved clinical studies or registries.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
Under CED, CMS provides coverage for promising items or services on the condition that beneficiaries are enrolled in an approved study or data collection effort that addresses outstanding questions. What the regulation says
Coverage with Evidence Development (CED) is a mechanism primarily used by the Centers for Medicare & Medicaid Services (CMS) in the United States to provide conditional coverage for medical technologies. This approach enables beneficiaries to access innovative items and services while systematically collecting additional evidence to assess their impact on health outcomes. The conditions for coverage often involve participation in studies or registries, as outlined by CMS policies.
What this means in practice
CED is common for novel devices with developing evidence (e.g., TAVR, leadless pacemakers historically). Registry participation requirements influence hospital adoption and total cost of evidence generation.Examples
- A novel cardiac implant receives CED from CMS, requiring all patients receiving the device to be enrolled in a specific post-market registry to collect long-term outcome data.
- A new diagnostic test is covered under CED, mandating that healthcare providers submit data on patient demographics and test results to a designated database to assess its clinical utility.
- CMS grants CED for a new cancer therapy, contingent on patients participating in an approved clinical trial that aims to further evaluate its efficacy in a broader patient population.
Common pitfalls
- •Manufacturers might underestimate the resources required for data collection and study participation under CED.
- •Failing to design studies that adequately address the evidence gaps identified by CMS can lead to delays or non-coverage.
- •Misinterpreting CMS requirements for data submission and study protocols can result in compliance issues.
- •Assuming that CED implies permanent coverage without the need for submitting conclusive evidence is a common misconception.
- •Ignoring the impact of CED on market access strategies and product launch timelines can lead to commercial challenges.
Frequently asked questions
The primary goal of CED is to facilitate patient access to promising new medical technologies while simultaneously gathering additional clinical evidence to determine their long-term effectiveness and appropriateness for coverage.
Cross-references
Used by
Things that build on this term.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsReimbursement
National and Local Coverage Determinations(NCD / LCD)
Medicare coverage policies issued nationally (NCD) or by individual MAC contractors (LCD).
Reimbursement
Transitional Coverage for Emerging Technologies(TCET)
CMS pathway providing time-limited Medicare coverage for FDA-designated Breakthrough Devices.
More in Reimbursement
· Same categoryReimbursement
340B Drug Pricing Program(340B)
Federal program providing discounted drugs to safety-net providers.
Reimbursement
Ambulatory Payment Classification(APC)
The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient.
Reimbursement
ASC Site-of-Service Shift
Migration of procedures from hospitals to ambulatory surgery centers.
Reimbursement
Budget Impact Model(BIM)
Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
CMS·1AMA·1AdvaMed·1
- 1
CMS CEDVerifiedCMScms.gov
- 2
AMA CPT ResourcesVerifiedAMAama-assn.org
- 3
AdvaMed - Payment & CoverageVerifiedAdvaMedadvamed.org
Inline markers like [1] jump to the matching reference above.